ADC Therapeutics (ADCT) Stock Price, News, Quotes-Moomoo

US Stock MarketDetailed Quotes

ADCT ADC Therapeutics

Watchlist

4.960
+0.520+11.71%

Close Apr 17 16:00 ET

5.050
+0.090+1.81%

Post 18:57 ET

409.35MMarket Cap-1687P/E (TTM)

Full Hours

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Express News | HC Wainwright & Co. Reiterates Buy on ADC Therapeutics, Maintains $9 Price Target
Moomoo 24/7Apr 15 07:51 ET
Buy Rating Affirmed for ADC Therapeutics on Strong Preclinical Data and Promising Trial Progress
TipRanksApr 15 06:16 ET
Analysts Conflicted on These Healthcare Names: ADC Therapeutics (ADCT), Adial Pharmaceuticals (ADIL) and Steris (STE)
TipRanksApr 11 11:30 ET
ADC Therapeutics Showcases Cancer Treatment Innovations
TipRanksApr 9 16:23 ET
Express News | Guggenheim Reiterates Buy on ADC Therapeutics
Moomoo 24/7Apr 5 09:55 ET
Sector Update: Health Care Stocks Slump Late Afternoon
Health care stocks fell late Thursday afternoon, with the NYSE Health Care Index and the Health Care Select Sector SPDR Fund (XLV) each dropping 1.3%. The iShares Biotechnology ETF (IBB) shed 1.4%. In
MT NewswiresApr 4 16:03 ET

Comments

Trytosaveabit

Apr 4 19:12

Update

$ADC Therapeutics(ADCT.US)$ ADC Therapeutics Announces Updates on LOTIS-7 Clinical Trial Evaluating ZYNLONTA in Combination With Glofitamab or Mosunetuzumab in Patients With Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma
Moomoo 24/7· 5 mins ago
ADC Therapeutics SA (NYSE:ADCT) today announced the completion of dose escalation in LOTIS-7, a Phase 1b open-label clinical trial evaluating ZYNLONTA (loncastuximab tesirine-lpyl) in combination with bispecific antibodies glofitamab or mosunetuzum...

Moomoo AI

Jan 20 03:04

ADC Therapeutics' low P/S ratio may be due to poor growth and declining revenue. The company's underwhelming revenue outlook and shareholders' pessimism on revenue prospects contribute to the low P/S. The share price is unlikely to rise strongly soon.

Improved Revenues Required Before ADC Therapeutics SA (NYSE:ADCT) Stock's 43% Jump Looks Justified

ETFWorldSavior

Jul 17, 2023 10:58

ColumnsADC Therapeutics | LOTIS-9 Combo Study Takes a Breather on Enrollment

ADCT before market open today announced its voluntary pause in the enrollment of the LOTIS-9 combo trial of Zynlonta and Rituxan (Lonca-R) in front-line unfit/frail DLBCL. We also caught up with the mgmt team this morning for more insights. Briefly, the pause was driven by higher-than-expected respiratory-related TEAEs (incl. 7 Gr 5, 5 Gr 3/4) after a recent data review of 40 pts. Of the 12 TEAEs, 1 Gr 5 case was deemed to be r...